Phase 2 N=621 Study of Cyclosporine in Post-LASIK Patients
Laser In Situ Keratomileusis
Primary: Time to Cure — 189.0; 194.0; 189.0 Days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Perennial Allergic Rhinoconjunctivitis · House Dust Mite Allergy
Primary: Conjunctival Provocation Test (CPT) With House Dust Mite Allergen Solutions. Change of Median Individual Allergen Tolerance Compared to Baseline (Factor of Increase in…
Phase 2 N=130 Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
Kidney Diseases · Kidney Transplantation · Kidney Transplant
Primary: The Difference in Linear Growth by Treatment Assignment at 1 Year Post Kidney Transplantation — 0.37; 0.35 Standard Deviation Score (SDS) — p=0.79
Phase 2 N=29 Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer · Stage III Ovarian Epithelial Cancer
Primary: Proportion of Patients Who Experience a Confirmed Response According to Modified RECIST Criteria. — 0.071; 0; 0; 0 proportion of participants
Phase 2 N=35 Metronidazole for Pulmonary Tuberculosis (South Korea)
Tuberculosis · Multi-Drug Resistant Tuberculosis
Primary: Changes in TB Lesion Sizes Using High Resolution Computed Tomography (HRCT). — 8.11; 10.08; 6.64; 7.24 reader score
Phase 2 N=39 Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) · Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Primary: The Number of Confirmed Disease Response: Complete Response (CR), Partial Response (PR), and Hematologic Improvement (HI). A Confirmed Response is Defined to be an…
Phase 2 N=44 Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Progression-free Survival at 6 Months — 0; 29 percentage of patients
Phase 2 N=63 Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants
Phase 2 N=21 Treatments for Recovery of Hand Function in Acute Stroke Survivors
Stroke, Acute · Stroke · Hemiparesis
Primary: Maximum Voluntary Finger Extension Angle (a Measure of Hand Impairment) — -11.6; -43.4 degrees
Phase 2 N=11 Interleukin-1 Trap to Treat Autoinflammatory Diseases
Inflammation · Familial Mediterranean Fever · Still's Disease, Adult-Onset
Primary: Mean Change in Daily Scores — -3.09 units on a scale
Phase 2 N=27 Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR). — 0; 1 participants
Phase 2 N=103 Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Proportion of Successes (Patients Alive and Progression-free) — 15.2; 26.7; 10 percentage of participants
Phase 2 N=79 D-Cycloserine Facilitation of Cocaine - Cue Extinction
Cocaine Use Disorders
Primary: Subjective Craving of Cocaine — 2.47; 0.90; 1.19; 1.06 units on a scale
Phase 2 N=13 Pegylated Interferon to Treat Chronic Hepatitis D
Hepatitis D
Primary: Histological Response at 3 Years — 6 participants
Phase 2 N=374 Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control
Influenza
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms After Vaccination — 45; 55; 1; 1 Participants